Kelvin, J. M., Jain, J., Thapa, A., Qui, M., Birnbaum, L. A., Moore, S. G., … Dreaden, E. C. (2023). Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML. https://doi.org/10.1101/2023.03.13.531236

Kelvin, James M., Juhi Jain, Aashis Thapa, Min Qui, Lacey A. Birnbaum, Samuel G. Moore, Henry Zecca, et al. “Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML.,” March 15, 2023. https://doi.org/10.1101/2023.03.13.531236.

Kelvin JM, Jain J, Thapa A, Qui M, Birnbaum LA, Moore SG, et al. Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML. 2023.

Kelvin, James M., et al. Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML. 15 Mar. 2023. Pubmed, doi:10.1101/2023.03.13.531236.

Kelvin JM, Jain J, Thapa A, Qui M, Birnbaum LA, Moore SG, Zecca H, Summers RJ, Costanza E, Uricoli B, Wang X, Jui NT, Fu H, Du Y, DeRyckere D, Graham DK, Dreaden EC. Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML. 2023.